Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening
Authors:
- Jeffrey W. TynerJTJeffrey W. Tyner
- Wayne F. YangWYWayne F. Yang
- Armand BankheadABArmand Bankhead
- Guang FanGFGuang Fan
- Luke B. FletcherLFLuke B. Fletcher
- Jade BryantJBJade Bryant
- Jason M. GloverJGJason M. Glover
- Bill H. ChangBCBill H. Chang
- Stephen E. SpurgeonSSStephen E. Spurgeon
- William H. FlemingWFWilliam H. Fleming
- Tibor KovacsovicsTKTibor Kovacsovics
- Jason R. GotlibJGJason R. Gotlib
- 1 January 2013
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 73 (1) , 285-296
Abstract
Kinases are dysregulated in most cancers, but the frequency of specific kinase mutations is low, indicating a complex etiology in kinase dysregulation. Here, we report a strategy to rapidly identify functionally important kinase targets, irrespective of the etiology of kinase pathway dysregulation, ultimately enabling a correlation of patient genetic profiles to clinically effective kinase inhibitors. Our methodology assessed the sensitivity of primary leukemia patient samples to a panel of 66 small-molecule kinase inhibitors over 3 days. Screening of 151 leukemia patient samples revealed a wide diversity of drug sensitivities, with 70% of the clinical specimens exhibiting hypersensitivity to one or more drugs. From this data set, we developed an algorithm to predict kinase pathway dependence based on analysis of inhibitor sensitivity patterns. Applying this algorithm correctly identified pathway dependence in proof-of-principle specimens with known oncogenes, including a rare FLT3 mutation outside regions covered by standard molecular diagnostic tests. Interrogation of all 151 patient specimens with this algorithm identified a diversity of kinase targets and signaling pathways that could aid prioritization of deep sequencing data sets, permitting a cumulative analysis to understand kinase pathway dependence within leukemia subsets. In a proof-of-principle case, we showed that in vitro drug sensitivity could predict both a clinical response and the development of drug resistance. Taken together, our results suggested that drug target scores derived from a comprehensive kinase inhibitor panel could predict pathway dependence in cancer cells while simultaneously identifying potential therapeutic options. Cancer Res; 73(1); 285–96. ©2012 AACR.Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- CREBBP mutations in relapsed acute lymphoblastic leukaemiaNature, 2011
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- JAK mutations in high-risk childhood acute lymphoblastic leukemiaProceedings of the National Academy of Sciences, 2009
- RNAi screen for rapid therapeutic target identification in leukemia patientsProceedings of the National Academy of Sciences, 2009
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences, 2008
- The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProceedings of the National Academy of Sciences, 2007
- Patterns of somatic mutation in human cancer genomesNature, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004